By Jerry Del Priore
After the Seattle Mariners inked infielder Danny Muno to a minor league contract in May, he has been taking full advantage of the opportunity. The Fresno State University product is hitting a solid .304 with four home runs, 16 RBI, 22 walks and 22 runs scored in 135 at-bats in 42 games with the Tacoma Rainiers of the Pacific Coast League (PCL).
Muno, a former Brooklyn Cyclone and New York Met, began the 2017 baseball season with the Southern Maryland Blue Crabs of the independent Atlantic League. The 28-year-old Long Beach, California, native batted .254 while slugging one dinger, driving in four runs, scoring nine runs, and stealing four bases in 59 at-bats in 18 games before signing with Seattle.
Muno had spent Spring Training with the Detroit Tigers, but was cut before the campaign started.
The six-foot-one-inch, 195-pound switch hitter made his MLB with the Mets on April 17, 2015. He went on to hit .148 in 27 at-bats in 17 tilts.
After New York selected him in the eighth round of the 2011 MLB amateur draft, the Mets shipped Muno to short-season Single-A Brooklyn to begin his professional career. He wound up slugging to the tune of an impressive .355 with two homers and 24 RBI along with a remarkable .466 on-base percentage and 22 doubles in 220 at-bats in 59 games with the Cyclones.
Muno’s stellar season earned him a spot on the New York-Penn League (NYPL) All-Star team, and New York named him as the Sterling Award winner for Brooklyn, symbolic of the team’s MVP.
While in college, the Western Athletic Conference named Muno as the Freshman of the Year after helping Fresno State win the College World Series Championship in 2008.
Additionally, he garnered first team All-WAC honors in 2009 and left Fresno State ranked first in school history in games played (259), runs scored (251) and walks (213). Muno also ranked second in hits (332) and doubles (69) and eighth in RBIs (156).
Of note, Muno received a 50-game suspension in 2012 after testing positive for a metabolite of Drostanolone, an anabolic-androgenic steroid (AAS).